Oxycodone News and Research

RSS

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Pfizer Inc. announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII.

22 Oct 2013

Breast cancer patients receiving nerve block with general anesthesia have less cancer recurrence

Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only general anesthesia, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

Metabolic enzymes in opium poppy are used to produce valuable painkilling drugs

University of Calgary scientists have discovered metabolic enzymes in the opium poppy that play "widespread roles" in enabling the plant to make painkilling morphine and codeine, and other important compounds.

5 Oct 2013

Study assess use of prescription painkillers for chronic pain among patients pre- and post-obesity surgery

Chronic use of prescription painkillers, also known as opioids, among obese patients prior to bariatric surgery continues after surgery, according to a new Kaiser Permanente study published today in the Journal of the American Medical Association.

2 Oct 2013

Research roundup: Managed care for dementia patients; bundled payments after the hospital; disparities among Medicare beneficiaries

Dementia is a leading cause of death in the United States; however, patients dying with this disease may not receive optimal end-of-life care. ... many of these [nursing home] residents commonly experience burdensome and costly interventions, such as hospital transfers, tube-feeding, and intravenous antibiotics. ... Nursing home reimbursement policies are among the factors that incentivize more aggressive care. ... This study linked unique prospective clinical data with Medicare claims to describe and compare patterns of care between nursing home residents with advanced dementia enrolled in a Medicare managed-care insurance plan and those with fee-for-service Medicare.

30 Sep 2013

FDA takes steps to restrict the use of pain meds

The Food and Drug Administration will require a class-wide label change for long-acting opioids aimed at limiting use of these drugs to patients with severe, refractory pain.

12 Sep 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Endo Eyes Generics Growth With $225M Boca Pharmacal Acquisition

...

28 Aug 2013

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

A new report from Simon Fraser University researcher Bohdan Nosyk calls for the expansion of heroin and opioid medical treatment to stem the increase of overdose deaths.

7 Aug 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Poor, less educated patients are less likely to receive opioid pain medications in emergency rooms

Patients in moderate to severe pain in emergency rooms across the U.S. are less likely to receive opioid pain medications if they are black, Hispanic, poor, or have less education, compared to more affluent patients, according to a University of Rochester Medical Center study reported in the Journal of General Internal Medicine.

27 Jun 2013

HHS inspector general details prescription-writing abuses

The new report finds that health providers such as massage therapists, chiropractors and athletic trainers often wrote prescriptions -- and Medicare paid for them.

25 Jun 2013

Novel approach to pain therapy paves way for lower dosage painkillers

For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.

11 Jun 2013

FDA to review QRxPharma's resubmitted MOXDUO NDA in July 2013

QRxPharma Limited announced today the US Food and Drug Administration has set 17 July 2013 as the date of the Advisory Committee meeting to consider the Company's resubmitted MOXDUO New Drug Application.

18 May 2013

Regularly taking prescription painkillers is associated with higher risk of ED in men

Regularly taking prescription painkillers, also known as opioids, is associated with a higher risk of erectile dysfunction (ED) in men, according to a study published online today in the journal Spine.

17 May 2013

DURECT: Pfizer provides update on investigational drug Remoxy

DURECT Corporation today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.

10 May 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Neura Therapeutik plans to speed up development of abuse-deterrent, generic extended-release opioids

Neura Therapeutik announced today that they will be accelerating the development of their abuse-deterrent brand and generic extended-release opioids.

19 Apr 2013